MaRS | May 15, 2009 Thomas G. Wellner – President & CEO Dr. David N. Bell – VP Drug Development & CSO www.therapurebio.com

of all new products The future of medicine 1 3 /

$51B $87B $25B $89B 2001 Protein therapeutic market 2005 2010 2010 Worldwide mobile technology market

You discovered a protein with blockbuster potential Specific Safe Targeted Efficacious Novel

Specific

Safe

Targeted

Efficacious

Novel

Ultimately, to get your product approved you will invest… You are working hard to develop it 11 years 5 clinical trials 2,000 patients 39 patents ~$1 billion

Ultimately, to get your product approved you will invest…

11 years

5 clinical trials

2,000 patients

39 patents

~$1 billion

What about manufacturing ?

Discovery Development Marketing Manufacturing

Scaling up is not easy Simple Quick Inexpensive Milligrams commercial bench Complex Long lead times - 4-5 years Expensive - $150 + million Kilograms

Simple

Quick

Inexpensive

Milligrams

Complex

Long lead times - 4-5 years

Expensive - $150 + million

Kilograms

Therapure Biopharma: Overcoming the manufacturing barrier Complex We know protein purification Long lead times Ready to go now Quality cGMP compliant Expensive Established Meadowpine Facility Regulated We have 8 INDs under our belts

Therapure Biopharma Inc. Flexible, modern cGMP manufacturing facility Expertise in manufacturing & downstream purification Extensive quality systems Deep understanding of advanced biology & complex proteins Creative partnering options Committed to the development, manufacture, purification, and packaging of high-quality biological therapeutics

Flexible, modern cGMP manufacturing facility

Expertise in manufacturing & downstream purification

Extensive quality systems

Deep understanding of advanced biology & complex proteins

Creative partnering options

Therapure Biopharma – Key Facts Company Established Assets of former Hemosol business acquired Q3/2007 including modern and flexible Health Canada approved facility Therapure Biopharma Inc. launched Q3/2008 Ownership Financing Privately held by Catalyst Fund Limited Partnership II, a Canadian based private equity fund, and management

Company Established

Assets of former Hemosol business acquired Q3/2007 including modern and flexible Health Canada approved facility

Therapure Biopharma Inc. launched Q3/2008

Ownership Financing

Privately held by Catalyst Fund Limited Partnership II, a Canadian based private equity fund, and management

Modern and Flexible Facility Facility Built: 2003 Size: 130,000 ft 2 (12,000 m 2 ) Location: Toronto, Canada (Mississauga) Minutes from Toronto’s Lester B. Pearson International Airport Employees: 65 Capabilities Development, manufacture and fill/finish of therapeutic proteins Product development Process development Manufacturing Fill/finish Lyophilization Designed to meet U.S. FDA, Health Canada and EMEA requirements

Facility Built: 2003

Size: 130,000 ft 2 (12,000 m 2 )

Location: Toronto, Canada (Mississauga)

Minutes from Toronto’s Lester B. Pearson International Airport

Employees: 65

Capabilities

Development, manufacture and fill/finish of therapeutic proteins

Product development

Process development

Manufacturing

Fill/finish

Lyophilization

Designed to meet U.S. FDA, Health Canada and EMEA requirements

Our Business Strategy Cornerstone CDMO Business Unique & Flexible Facility Scientific & Biomanufacturing Expertise Creative Financing Develop Products TBI Pipeline Joint Venture

Develop Products

TBI Pipeline

Joint Venture

Key Milestones Therapure Biopharma Inc. established July/08 Manufacturing plant re-validated Sept/08 Key talent retained and hired Plant upgraded to create flexible multi-use facility Dec/08 Several key partner/client agreements executed Revenue generation in 2008 Break even goal in 2009 Business development activities increasing Pipeline milestones achieved for core assets Health Canada re-certification of plant – May/09

Therapure Biopharma Inc. established July/08

Manufacturing plant re-validated Sept/08

Key talent retained and hired

Plant upgraded to create flexible multi-use facility Dec/08

Several key partner/client agreements executed

Revenue generation in 2008

Break even goal in 2009

Business development activities increasing

Pipeline milestones achieved for core assets

Health Canada re-certification of plant – May/09

Key Clients / Global Collaborations Client project opportunities continue to grow Rare protein development project Growth factors for stimulating bone regeneration Iron Chelating Agent for thalassemia PEGylated biologic oncology product

Client project opportunities continue to grow

Rare protein development project

Growth factors for stimulating bone regeneration

Iron Chelating Agent for thalassemia

PEGylated biologic oncology product

Experienced Sr. Management Team Thomas Wellner President and CEO Eli Lilly & Co. Dirk Alkema, Ph.D. Vice President, Operations Connaught Labs and Hemosol Peter Winkley, CA Vice President Finance and CFO MDS and Ernst & Young David Bell, Ph.D. Vice President, Drug Development and CSO BioChem Therapeutic Inc and FAA

Thomas Wellner President and CEO Eli Lilly & Co.

Dirk Alkema, Ph.D. Vice President, Operations Connaught Labs and Hemosol

Peter Winkley, CA Vice President Finance and CFO MDS and Ernst & Young

David Bell, Ph.D. Vice President, Drug Development and CSO BioChem Therapeutic Inc and FAA

Sophisticated Biologic Development & Manufacturing Services

Integrated Full Service Provider “ One stop-shop ” for development and manufacture of therapeutic proteins Cost-effectively manage all aspects of development and manufacturing at both small (mg) and large (kg) scale: Upstream processing Downstream processing Clinical supplies including distribution Commercial manufacturing Fill and finish Lyophilization Full analytical support

“ One stop-shop ” for development and manufacture of therapeutic proteins

Cost-effectively manage all aspects of development and manufacturing at both small (mg) and large (kg) scale:

Upstream processing

Downstream processing

Clinical supplies including distribution

Commercial manufacturing

Fill and finish

Lyophilization

Full analytical support

Fully Integrated Services Upstream Processing Molecular biology Cell line creation &banking Mammalian cell cultures Downstream Processing Protein modification Purification Stabilization mg to kg scale batches Preclinical scale Clinical scale Commercial scale Aseptic filling of glass vials & preformed bags Lyophilization Clinical supplies including distribution Commercial Product

Upstream Processing

Molecular biology

Cell line creation &banking

Mammalian cell cultures

Downstream Processing

Protein modification

Purification

Stabilization

mg to kg scale batches

Preclinical scale

Clinical scale

Commercial scale

Aseptic filling of glass vials & preformed bags

Lyophilization

Clinical supplies including distribution

High Quality Manufacturing Facility Chromatography Analytical Laboratory Vial filling line Buffer farm

Support Beyond Development & Manufacturing

Creative Financing Opportunities Therapure can potentially offer creative financing to partners who require development and biomanufacturing services: Secured Debt Equity partnership Joint Venture

Therapure can potentially offer creative financing to partners who require development and biomanufacturing services:

Secured Debt

Equity partnership

Joint Venture

Your trusted partner for protein development & manufacturing www.therapurebio.com

Your trusted partner for protein development & manufacturing